Vivoryon Therapeutics Reports Q1 2026 Loss, Highlights Kidney-Disease Data and Funding Needs

When the next wave of kidney‑disease treatments is on the horizon, Vivoryon Therapeutics’ Q1 results paint a clear p...

Read story →